Navigation Links
Arthritic Drug Approved For Use In Children With Crohn’s Diseas

The Food and Drug Administration in the U.S. have given an approval for the drug Remicade for use in children with active Crohn's disease (CD), which is a chronic// and debilitating condition.

Crohn's disease is an inflammation of the gastrointestinal tract that causes diarrhea, fever, abdominal pain, weight loss and, in some times, delayed development and stunted growth. Though it can involve any area of the gastrointestinal tract from the mouth to the anus, it commonly affects the small intestine.

Remicade has already been approved for treating rheumatoid arthritis and other conditions but now the drug will carry an additional warning about the small risk of an often-fatal lymphoma. It has been found that Remicade and other TNF blockers, may increase the risk of lymphoma or other cancers, and is not recommended for people with heart failure. There are also reports on the drug as it could cause serious infections, including tuberculosis (TB), sepsis and pneumonia, liver injury, and blood disorders.

According to drug company Johnson & Johnson the drug is the first and only biologic therapy that has been approved for the treatment of pediatric Crohn's disease. The officials said that the drug helps in reducing the signs and symptoms of the disease and helps to maintain remission in children suffering from moderate or severe form of Crohn’s disease, and those who have not responded to regular treatment.

The approval was passed after a data from a clinical trial of 112 patients aged 6 to 17 years, found that the children with moderate to severe active Crohn's disease after 10 weeks of therapy with Remicade responded well and more than half were in remission at the end of one year.

Approximately 100,000 children under the age of 17 suffer from inflammatory bowel diseases (IBD), which include CD and ulcerative colitis (UC). Remicade, known generically as infliximab, belongs to a class of drugs that suppress tumo r necrosis factor-alpha, a protein involved in inflammation.
'"/>




Related medicine news :

1. Do Arthritics Perceive the Importance of Exercise in the Management of Disease?
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
10. Pfizer’s Eraxis Approved By The FD
11. Inhalers for Kids Was Approved By the FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... 26, 2017 , ... Want to learn more about CRISPR-Cas ... that demonstrates how this advanced plant breeding technology is a more efficient way ... resources. It highlights the business’ principles, research and collaboration efforts in this area. ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, a medical ... that it has received 510(k) clearance from the U.S. Food & Drug Administration ... Pro. , Both devices are stationary cycling systems that use MYOLYN’s patent-pending ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab ... to be the preferred physical therapy provider for Derby City CrossFit, effective immediately. ... City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology: